fr   en
Clinical Studies

Browse by date
Or search by keyword
Date: 2006-01-09
Phase: II
Anouncement: Launch
Biotech: Gilead Sciences (USA)
Product: JTK-303 or GS 9137 (HIV integrase inhibitor)
Disease: AIDS
Other: The product comes from a license granted by Japan Tobacco. It is orally administered and the planned phase II clinical trial will evaluate three daily doses of GS 9137 (20, 50 and 125 mg) taken in combined with 100 mg of ritonavir.